NEW YORK – Researchers in Germany have uncovered two subtypes of pancreatic cancer, one of which is more aggressive but could also be susceptible to a targeted therapy.
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a five-year survival rate of about 9 percent. To examine the mutational landscape of the disease, which accounts for most cases of pancreatic cancer, researchers from the German Cancer Research Center (DFKZ) teased out pancreatic epithelial cells from PDAC tumors and normal pancreatic tissue.